Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 1, 2016, Pages 71-80

  Charles Schoeman, Christina ^a   Gonzalez Gay, Miguel A ^b   Kaplan, Irina ^c   Boy, Mary ^c   Geier, Jamie ^c   Luo, Zhen ^c   Zuckerman, Andrea ^c   Riese, Richard ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c PFIZER INC   (United States)

Author keywords

Disease modifying antirheumatic drugs; Janus kinase; Rheumatoid arthritis; TNF inhibitors; Tofacitinib

Indexed keywords

CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TOFACITINIB; ANTIRHEUMATIC AGENT; LIPID; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; LIPID ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; BLOOD;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; LIPIDS; PIPERIDINES; PYRIMIDINES; PYRROLES; RHEUMATOLOGY;

EID: 84964331027     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.03.004     Document Type: Review

References (84)

1. [1] Avina-Zubieta, J.A., Thomas, J., Sadatsafavi, M., Lehman, A.J., Lacaille, D., Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71 (2012), 1524–1529.
2. [2] Gonzalez, A., Maradit, K.H., Crowson, C.S., Ballman, K.V., Roger, V.L., Jacobsen, S.J., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 67 (2008), 64–69.
3. [3] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Lopez-Diaz, M.J., Pineiro, A., Garcia-Porrua, C., Miranda-Filloy, J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57 (2007), 125–132.
4. [4] Gabriel, S.E., Crowson, C.S., Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 24 (2012), 171–176.
5. [5] Johnsson, H., Panarelli, M., Cameron, A., Sattar, N., Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions. Ann Rheum Dis 73 (2014), 1495–1499.
6. [6] Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 56, 2010 e50–103.
7. [7] Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 33 (2012), 1635–1701.
8. [8] Ridker, P.M., Rifai, N., Clearfield, M., Downs, J.R., Weis, S.E., Miles, J.S., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001), 1959–1965.
9. [9] Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M. Jr., Kastelein, J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
10. [10] National Cholesterol Education Program Expert Panel, Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation 106 (2002), 3143–3421.
11. [11] Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989), 8–15.
12. [12] Bishop, B.M., Systematic Review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?. Am J Ther 22 (2015), 147–158.
13. [13] de la Llera Moya, M., McGillicuddy, F.C., Hinkle, C.C., Byrne, M., Joshi, M.R., Nguyen, V., et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis 222 (2012), 390–394.
14. [14] Myasoedova, E., Crowson, C.S., Kremers, H.M., Fitz-Gibbon, P.D., Therneau, T.M., Gabriel, S.E., Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 69 (2010), 1310–1314.
15. [15] Akgun, S., Ertel, N.H., Mosenthal, A., Oser, W., Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med 131 (1998), 103–108.
16. [16] Marik, P.E., Dyslipidemia in the critically ill. Crit Care Clin 22 (2006), 151–159 [viii].
17. [17] Vermont, C.L., den Brinker, M., Kakeci, N., de Kleijn, E.D., de Rijke, Y.B., Joosten, K.F., et al. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 33 (2005), 1610–1615.
18. [18] Myasoedova, E., Crowson, C.S., Kremers, H.M., Roger, V.L., Fitz-Gibbon, P.D., Therneau, T.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70 (2011), 482–487.
19. [19] Ajeganova, S., Andersson, M.L., Frostegard, J., Hafstrom, I., Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 40 (2013), 1958–1966.
20. [20] Morgan, C.L., Emery, P., Porter, D., Reynolds, A., Young, A., Boyd, H., et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 53 (2014), 186–194.
21. [21] Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74 (2015), 480–489.
22. [22] Greenberg, J.D., Kremer, J.M., Curtis, J.R., Hochberg, M.C., Reed, G., Tsao, P., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 576–582.
23. [23] Boers, M., Nurmohamed, M.T., Doelman, C.J., Lard, L.R., Verhoeven, A.C., Voskuyl, A.E., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003), 842–845.
24. [24] Georgiadis, A.N., Papavasiliou, E.C., Lourida, E.S., Alamanos, Y., Kostara, C., Tselepis, A.D., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment—a prospective, controlled study. Arthritis Res Ther, 8, 2006, R82.
25. [25] Morris, S.J., Wasko, M.C., Antohe, J.L., Sartorius, J.A., Kirchner, H.L., Dancea, S., et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 63 (2011), 530–534.
26. [26] Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (2007), 1162–1167.
27. [27] Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008), 987–997.
28. [28] Maini, R.N., Taylor, P.C., Szechinski, J., Pavelka, K., Broll, J., Balint, G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006), 2817–2829.
29. [29] Emery, P., Keystone, E., Tony, H.P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (2008), 1516–1523.
30. [30] Genovese, M.C., McKay, J.D., Nasonov, E.L., Mysler, E.F., da Silva, N.A., Alecock, E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58 (2008), 2968–2980.
31. [31] Jones, G., Sebba, A., Gu, J., Lowenstein, M.B., Calvo, A., Gomez-Reino, J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69 (2010), 88–96.
32. [32] Yamanaka, H., Tanaka, Y., Inoue, E., Hoshi, D., Momohara, S., Hanami, K., et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 21 (2011), 122–133.
33. [33] Burmester, G.R., Feist, E., Kellner, H., Braun, J., Iking-Konert, C., Rubbert-Roth, A., Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70 (2011), 755–759.
34. [34] Yazici, Y., Curtis, J.R., Ince, A., Baraf, H., Malamet, R.L., Teng, L.L., et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 71 (2012), 198–205.
35. [35] McInnes, I.B., Thompson, L., Giles, J.T., Bathon, J.M., Salmon, J.E., Beaulieu, A.D., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 74 (2015), 694–702.
36. [36] van Sijl, A.M., Peters, M.J., Knol, D.L., de Vet, R.H., Sattar, N., Dijkmans, B.A., et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 41 (2011), 393–400.
37. [37] Daien, C.I., Duny, Y., Barnetche, T., Daures, J.P., Combe, B., Morel, J., Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71 (2012), 862–868.
38. [38] Kirkham, B.W., Wasko, M.C., Hsia, E.C., Fleischmann, R.M., Genovese, M.C., Matteson, E.L., et al. Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 73 (2014), 161–169.
39. [39] Jamnitski, A., Visman, I.M., Peters, M.J., Dijkmans, B.A., Voskuyl, A.E., Nurmohamed, M.T., Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 69 (2010), 1929–1933.
40. [40] Kremer, J.M., Bloom, B.J., Breedveld, F.C., Coombs, J.H., Fletcher, M.P., Gruben, D., et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60 (2009), 1895–1905.
41. [41] Kremer, J.M., Cohen, S., Wilkinson, B.E., Connell, C.A., French, J.L., Gomez-Reino, J., et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64 (2012), 970–981.
42. [42] Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., Zwillich, S.H., Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63 (2011), 1150–1158.
43. [43] Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
44. [44] Kremer, J., Li, Z.G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159 (2013), 253–261.
45. [45] van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65 (2013), 559–570.
46. [46] van Vollenhoven, R.F., Fleischmann, R., Cohen, S., Lee, E.B., García Meijide, J.A., Wagner, S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367 (2012), 508–519.
47. [47] Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367 (2012), 495–507.
48. [48] Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J., Gruben, D., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
49. [49] Pfizer Inc. Tofacitinib for the treatment of rheumatoid arthritis. NDA 203214. Briefing document. 〈http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf〉; Accessed March 29, 2016.
50. [50] Criqui, M.H., Golomb, B.A., Epidemiologic aspects of lipid abnormalities. Am J Med 105:1A (1998), 48S–57S.
51. [51] Millan, J., Pinto, X., Munoz, A., Zuniga, M., Rubies-Prat, J., Pallardo, L.F., et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 5 (2009), 757–765.
52. [52] Riley, S.P., Boy, M.G., Riese, R., Krishnaswami, S., Low density lipoprotein (LDL c) exposure-response analysis for tofacitinib (CP-690,550) in patients with rheumatoid arthritis. Clin Pharmacol Ther, 91(Suppl. 1), 2012, S30 [abstract PI-63].
53. [53] Strand, V., Isaacs, J.D., Beal, J., Nduaka, C.I., Krishnaswami, S., Riese, R., et al. Association of mean changes in laboratory safety parameters with C-reactive protein at baseline and week 12 in rheumatoid arthritis patients treated with tofacitinib. Ann Rheum Dis, 73(Suppl. 2), 2014, 229.
54. [54] McInnes, I.B., Kim, H.Y., Lee, S.H., Mandel, D., Song, Y.W., Connell, C.A., et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 73 (2014), 124–131.
55. [55] Souto, A., Salgado, E., Maneiro, J.R., Mera, A., Carmona, L., Gomez-Reino, J.J., Lipid profile changes in patients with chronic inflammatory arthritis treated with biologics and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67 (2015), 117–127.
56. [56] Navarro-Millan, I., Charles-Schoeman, C., Yang, S., Bathon, J.M., Bridges, S.L. Jr., Chen, L., et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 65 (2013), 1430–1438.
57. [57] Charles-Schoeman, C., Fleischmann, R., Davignon, J., Schwartz, H., Turner, S., Beysen, C., et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 67 (2015), 616–625.
58. [58] Turner, S., Voogt, J., Davidson, M., Glass, A., Killion, S., Decaris, J., et al. Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc, 1, 2012, e001826.
59. [59] Eren, E., Yilmaz, N., Aydin, O., High density lipoprotein and it′s dysfunction. Biochem J 6 (2012), 78–93.
60. [60] Watanabe, J., Charles-Schoeman, C., Miao, Y., Elashoff, D., Lee, Y.Y., Katselis, G., et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64 (2012), 1828–1837.
61. [61] Charles-Schoeman, C., Lee, Y.Y., Grijalva, V., Amjadi, S., FitzGerald, J., Ranganath, V.K., et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71 (2012), 1157–1162.
62. [62] Vivekanandan-Giri, A., Slocum, J.L., Byun, J., Tang, C., Sands, R.L., Gillespie, B.W., et al. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1725–1731.
63. [63] Bhattacharyya, T., Nicholls, S.J., Topol, E.J., Zhang, R., Yang, X., Schmitt, D., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J Am Med Assoc 299 (2008), 1265–1276.
64. [64] Ikeda, Y., Inoue, M., Suehiro, T., Arii, K., Kumon, Y., Hashimoto, K., Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 46 (2009), 239–242.
65. [65] Charles-Schoeman, C., Lee, Y.Y., Shahbazian, A., Gorn, A.H., FitzGerald, J., Ranganath, V.K., et al. Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65 (2013), 2765–2772.
66. [66] Lopez-Mejias, R., Genre, F., Corrales, A., Gonzalez-Juanatey, C., Ubilla, B., Llorca, J., et al. Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 73 (2014), 1749–1750.
67. [67] Popa, C., van Tits, L.J., Barrera, P., Lemmers, H.L., van den Hoogen, F.H., van Riel, P.L., et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 68 (2009), 868–872.
68. [68] Metes, I.D., Chew, D.W., Patel, A.M., Balasubramani, G.K., Bridges, S.L., Curtis, J.R., et al. Anti-tumor necrosis factor a therapy (etanercept) plus methotrexate lowers serum amyloid a levels to a greater extent than triple oral disease modifying anti-rheumatic drug therapy in early rheumatoid arthritis subjects. Arthritis Rheum, 65(Suppl. 10), 2013, S626.
69. [69] McInnes, I., Kaplan, I., Boy, M., Riese, R., Zuckerman, A., Gruben, D., et al. Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis. Ann Rheum Dis, 72(Suppl. 3), 2013, 416.
70. [70] Robertson, J., Peters, M.J., McInnes, I.B., Sattar, N., Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9 (2013), 513–523.
71. [71] Crowson, C.S., Matteson, E.L., Roger, V.L., Therneau, T.M., Gabriel, S.E., Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 110 (2012), 420–424.
72. [72] Gomez-Vaquero, C., Corrales, A., Zacarias, A., Rueda-Gotor, J., Blanco, R., Gonzalez-Juanatey, C., et al. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther, 15, 2013, R91.
73. [73] Gonzalez-Gay, M.A., Gonzalez-Juanatey, C., Llorca, J., Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?. Ann Rheum Dis 71 (2012), 796–798.
74. [74] Corrales, A., Parra, J.A., Gonzalez-Juanatey, C., Rueda-Gotor, J., Blanco, R., Llorca, J., et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 72 (2013), 1764–1770.
75. [75] Corrales, A., Gonzalez-Juanatey, C., Peiro, M.E., Blanco, R., Llorca, J., Gonzalez-Gay, M.A., Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 73 (2014), 722–727.
76. [76] Kerola, A.M., Nieminen, T.V., Virta, L.J., Kautiainen, H., Kerola, T., Pohjolainen, T., et al. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000–2008. Clin Exp Rheumatol 33 (2015), 391–398.
77. [77] Khraishi, M., Aslanov, R., Effect of biologic disease modifiers on cardiovascular risk of patients with rheumatoid arthritis—2 years prospective cohort study [abstract]. Arthritis Rheum, 65, 2013, 382.
78. [78] Rao, V.U., Pavlov, A., Klearman, M., Musselman, D., Giles, J.T., Bathon, J.M., et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 67 (2015), 372–380.
79. [79] Yamamoto, K., Goto, H., Hirao, K., Nakajima, A., Origasa, H., Tanaka, K., et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol 42 (2015), 1368–1375.
80. [80] Charles-Schoeman, C., Wicker, P., Sechtem, U., Gonzalez-Gay, M.A., Wood, S., Boy, M., et al. Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral JAK inhibitor. Ann Rheum Dis, 71(Suppl. 3), 2012, 201.
81. [81] Charles-Schoeman, C., Wicker, P., Gonzalez-Gay, M.A., Boy, M., Zuckerman, A., Soma, K., et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor, 2015 Manuscript submitted for publication.
82. [82] Akkara Veetil, B.M., Myasoedova, E., Matteson, E.L., Gabriel, S.E., Crowson, C.S., Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol 40 (2013), 1082–1088.
83. [83] Pfizer Inc. Xeljanz prescribing information. 〈http://labeling.pfizer.com/ShowLabeling.aspx?id=959〉; Accessed March 29, 2016.
84. [84] De Vera, M.A., Choi, H., Abrahamowicz, M., Kopec, J., Lacaille, D., Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 64 (2012), 809–816.